Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 38, S1–93 (2015).

  • [2]L Guariguata, DR Whiting, I Hambleton, J Beagley, U Linnenkamp, JE Shaw: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103(2), 137-49 (2014)

  • [3]JE Shaw, RA Sicree, PZ Zimmet: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 87, 4–14 (2010)

  • [4]VA Kangralkar, SD Patil, RM Bandivadekar: Oxidative Stress and Diabetes: a Review. Int J Pharm Appl, 1, 38–45 (2010)

  • [5]U Asmat, K Abad, K Ismail: (in press) Diabetes mellitus and oxidative stress - A concise review. Saudi Pharm J. (2015)

  • [6]BM Fisher, G Gillen, GB Lindop, HJ Dargie, BM Frier: Cardiac function and coronary arteriography in asymptomatic type 1 (insulin-dependent) diabetic patients: evidence for a specific diabetic heart disease. Diabetologia 29, 706–12 (1986)

  • [7]K Mizushige, L Yao, T Noma, H Kiyomoto, Y Yu, N Hosomi, K Ohmori, H Matsuo: Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101, 899-907 (2000)

  • [8]TJ Regan, MM Lyons, SS Ahmed, GE Levinson, HA Oldewurtel, MR Ahmad, B Haider: Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60, 885–99 (1977)

  • [9]ZY Fang, JB Prins, TH Marwick: Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25, 543–67 (2004).

  • [10]C Voulgari, D Papadogiannis, N Tentolouris: Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Heart Risk Manag. 6, 883–903 (2010).

  • [11]SA Hayat, B Patel, RS Khattar, RA Malik: Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clinical Science 107, 539–57 (2004).

  • [12]K Huynh, JR McMullen, TL Julius, JW Tan, JE Love, N Cemerlang, H Kiriazis, XJ Du, RH Ritchie: Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 59, 1512–20 (2010)

  • [13]K Huynh, H Kiriazis, XJ Du, JE Love, SP Gray, KA Jandeleit-Dahm, JR McMullen, RH Ritchie: Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med 60, 307–17 (2013).

  • [14]D Westermann, S Rutschow, S Jäger, A Linderer, S Anker, A Riad, T Unger, HP Schulteiss, M Pauschinger. C Tschöpe: Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 reeceptor antagonism. Diabetes 56, 641–6 (2007)

  • [15]W Zhou, J Yang, DI Zhang, F Li, G Li, Y Gu, M Luo: Role of Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 in myocardial cells in diabetes. Exp Ther Med 10, 67–73 (2015)

  • [16]ZX Shan, QX Lin, CY Deng, JN Zhu, LP Mai, JL Liu, YH Fu, XY Liu, YX Li, YY Zhang, SG Lin, XY Yu: MiR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes. FEBS Lett. 584, 3592–600 (2010)

  • [17]SA Fatumo, MP Adoga, OO Ojo, O Oluwagbemi, T Adeoye, I Ewejobi, M Adebiyi, E Adebiyi, C Bewaji, O Nashiru: Computational biology and bioinformatics in Nigeria. PLoS Comput Biol. 10, 1-7 (2014)

  • [18]F Chen, X Zhao, J Peng, L Bo, B Fan, D Ma. Integrated microRNA-mRNA analysis of coronary artery disease. Mol Biol Rep 41, 5505–11 (2014)

  • [19]GEO DataSets - NCBI. http://www.ncbi.nlm.nih.gov/gds/term= (2015)

  • [20]LK Gerber, BJ Aronow, M Matlib: Activation of a novel long-chain free fatty acid generation and export system in mitochondria of diabetic rat hearts. Am J Physiol Cell Physiol 291, C1198–207 (2006)

  • [21]SK Raut, A Kumar, GB Singh, U Nahar, V Sharma, A Mittal, R Sharma, M Khullar: miR-30c mediates upregulation of Cdc42 and Pak1 in diabetic cardiomyopathy. Cardiovasc Ther 33, 89–97 (2015)

  • [22]GEO2R web application – NCBI. http://www.ncbi.nlm.nih.gov/geo/geo2r/ (2015)

  • [23]V Agarwal, GW Bell, J-W Nam, DP Bartel: Predicting effective microRNA target sites in mammalian mRNAs. Elife 4:e05005, 1-38 (2015)

  • [24]GK Smyth: Limma: linear models for microarray data. In: Bioinformatics and Computational biology solutions using R and Bioconductor, R Gentleman, V Carey, S Dudoit, R Irizarry, W Huber (eds.), Springer, New York, 397-420.

  • [25]M Murakami, Y Taketomi, H Sato, K Yamamoto: Secreted phospholipase A2 revisited. J Biochem 150, 233–55 (2011)

  • [26]B Ivandic, LW Castellani, XP Wang, JH Qiao, M Mehrabian, M Navab, AM Fogelman, DS Grass, ME Swanson, MC de Beer, F de Beer, AJ Lusis: Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arter Thromb vasc Biol. 19, 1284–90 (1999)

  • [27]O Muller, A Ntalianis, W Wijns, L Delrue, K Dierickx, R Auer, N Rodondi, F Mangiacapra, C Trana, M Hamilos, E Valentin, B De Bruyne, E Barbato, J Bartunek: Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease. J Cardiovasc Transl Res 6, 536-44 (2013)

  • [28]Z Mallat, G Steg, J Benessiano, ML Tanguy, KA Fox, JP Collet, OH Dabbous, P Henry, KF Carruthers, A Dauphin, CS Arguelles, J Masliah, B Hugel, G Montalescot, JM Freyssinet, B Asselain, A Tedgui: Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 46, 1249-57 (2005)

  • [29]C Wang, S Gu, H Cao, Z Li, Z Xiang, K Hu, X Han: miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis. Sci. Rep. 6:30122, 1-11 (2016)

  • [30]C-L Song, B Liu, H-Y Diao, Y-F Shi, J-C Zhang, Y-X Li, N Liu, Y-P Yu, G Wang, J-P Wang, Q Li: Down-regulation of microRNA-320 suppresses cardiomyocyte apoptosis and protects against myocardial ischemia and reperfusion injury by targeting IGF-1. Oncotarget 7(26), 39740-57 (2016)

  • [31]M Katoh. Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol 2, 1–19 (2014)

  • [32]HQ Lu, C Liang, ZQ He, M Fan, ZG Wu: Circulating miR-214 is associated with the severity of coronary artery disease. J Geriatr Cardiol 10, 34–8 (2013)

  • [33]AB Aurora, AI Mahmoud, X Luo, BA Johnson, E van Rooij, S Matsuzaki, KM Humphries, JA Hill, R Bassel-Duby, HA Sadek, EN Olson: MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca2+ overload and cell death. J Clin Invest. 122, 1222–32 (2012)

  • [34]R Nederlof, O Eerbeek, MW Hollmann, R Southworth, CJ Zuurbier: Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart. Br J Pharmacol. 171, 2067–79 (2014)

  • [35]JE Wilson: Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206, 2049–57 (2003)

  • [36]P Pasdois, JE Parker, AP Halestrap: Extent of mitochondrial hexokinase II dissociation during ischemia correlates with mitochondrial cytochrome c release, reactive oxygen species production, and infarct size on reperfusion. J Am Heart Assoc. 2, 1-20 (2012)

  • [37]R Wu, E Wyatt, K Chawla, M Tran, M Ghanefar, M Laakso, CL Epting, H Ardehali: Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production. EMBO Mol Med. 4, 633–46 (2012)

  • [38]W Du, Z Pan, X Chen, L Wang, Y Zhang, S Li, H Liang, C Xu, Y Zhang, Y Wu, H Shan, Y Lu: By targeting Stat3 microRNA-17-5p promotes cardiomyocyte apoptosis in response to ischemia followed by reperfusion. Cell. Physiol. Biochem. 34, 955-65 (2014)

  • [39]U Chaudhari, H Nemade, JA Gaspar, J Hescheler, JG Hengstler, A Sachinidis: MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes. Arch. Toxicol., 1-12 (2016)

  • [40]G Holmgren, J Synnergren, CX Andersson, A Lindahl, P Sartipy: MicroRNAs as pontential biomarkers for doxorubicin-induced cardiotoxicity. Toxicol. in vitro 34, 26-34 (2016)

  • [41]Y Yang, H-W Cheng, Y Qiu, D Dupee, M Noonan, Y-D Lin, S Fisch, K Unno, K-I Sereti, R Liao: MicroRNA-34-a plays a key role in cardiac repair and regeneration following myocardial infarction. Circ. Res. 117(5), 450-9 (2015)

  • [42]B Yang, S Ma, Y-B Wang, B Xu, H Zhao, Y-Y He, C-W Li, J Zhang, Y-K Cao, Q-Z Feng: Resveratrol exerts protective effects on anoxia/reoxygenation injury in cardiomyocytes via miR-34a/Sirt1 signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 20, 2734-41 (2016)

  • [43]MN Hirt, T Werner, D Indenbirken, M Alawi, P Demin, A-C Kunze, J Stenzig, J Starbatty, A Hansen, J Fiedler, T Thum, T Eschenhagen: Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. J. Mol. Cell. Cardiol. 81, 1-9 (2015)

  • [44]E Merlet, F Atassi, RK Motiani, N Mougenot, A Jacquet, S Nadaud, T Capiod, M Trebak, A-M Lompré, A Marchand: miR-424/322 regulates vascular smooth muscle cell phenotype and neointimal formation in the rat. Cardiovasc. Res. 98, 458-68 (2013)

  • [45]SR Joshi, V Dhagia, S Gairhe, JG Edwards, IF McMurtry, SA Gupte: MicroRNA-140 is elevated and mitofusin-1 is down-regulated in the right ventricle of the Sugen5416/hypoxia/normoxia model of pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol 311, H689-98 (2016)

  • [46]H Liang, C Zhang, T Ban, Y Liu, L Mei, X Piao, D Zhao, Y Lu, W Chu, B Yang: A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis. Int. J. Biochem. Cell. B. 44, 2152-60 (2012)

  • [47]K Wang, C-Y Liu, L-Y Zhou, J-X Wang, B Zhao, W-K Zhao, S-J Xu, L-H Fan, X-J Zhang, C-Q Wang, Y-F Zhao, P-F Li: APF IncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat. Commun. 6:6779, 1-11 (2015)

  • [48]PK Mishra, N Tyagi, S Kundu, SC Tyagi: MicroRNAs are involved in homocysteine-induced cardiac remodeling. Cell Biochem. Biophys. 55(3), 153-62 (2009)

  • [49]J Mo, D Zhang, R Yang: MicroRNA-195 regulates proliferation, migration, angiogenesis and autophagy of endothelial progenitor cells by targeting GABARAPL1. Biosci. Rep. 36, 1-11 (2016)

  • [50]H Bugger, ED Abel: Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57, 660–71 (2014).

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Mar 2017Article

mRNA-miRNA integrative analysis of diabetes-induced cardiomyopathy in rats

Mariana B. Lopes 1, Renata C. C. Freitas 1, Mario H. Hirata 2, Rosario D. C. Hirata 2, Adriana A. Rezende 1, Vivian N. Silbiger 1, Raul H. Bortolin 1, Andre D. Luchessi 1,*
Affiliations
Article Info

1 Department of Clinical and Toxicological Analyses, Federal University of Rio Grande do Norte. General Cordeiro de Farias Av., Natal, Rio Grande do Norte, 59012-570, Brazil

2 Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo. 580 B17 Lineu Prestes Av., Butantan,05508-900. Sao Paulo, Brazil

*Author to whom correspondence should be addressed.

 

Abstract

An integrative analysis of miRNA and mRNA expression profiles in left ventricle (LV) of diabetes-induced rats was performed to elucidate the role of miRNAs and their mRNAs target in diabetic cardiomyopathy (DCM). mRNA (GSE4745) and miRNA (GSE44179) datasets were downloaded from Gene Expression Omnibus 2R (GEO2R) and differentially expressed mRNAs and miRNAs were selected. Cardiotoxicity-related mRNAs (n=7) were analyzed by Ingenuity Pathway Analyses 6 (IPA) and regulatory miRNAs (n=639) were identified using TargetScan 7.1. web dataset. The integrative analysis was performed between miRNAs differentially expressed in GSE44179 and regulatory TargetScan-detected miRNAs of mRNAs differentially expressed in GSE4745. Pla2g2a and Hk2 mRNAs were up-and-down regulated, respectively, in GSE4745 on days 3 and 42 after diabetes-induction. The Pla2g2a regulatory miRNAs, rno-miR-877, rno-miR-320 and rno-miR-214, were down-regulated, and Hk2 regulatory miRNAs, rno-miR-17, rno-miR-187, rno-miR-34a, rno-miR-322, rno-miR-188, rno-miR-532 and rno-miR-21, were up-regulated in GSE44179 dataset. These results are suggestive that Pla2g2a and Hk2 mRNAs and their regulatory miRNAs play a role in DCM pathogenesis and they may be potential circulating biomarkers to detect early cardiovascular complications in diabetic patients.

Keywords

  • In silico analysis
  • Biomarkers
  • Diabetic Cardiomyopathy
  • Gene Expression
  • MicroRNAs

References